Antibacterial compound, and molding product comprising antibacterial resin

Compounds with non-halogen anions enhance solubility and safety, addressing limitations of halogen-substituted antimicrobial agents, ensuring broad applicability and effective antibacterial performance across various solvents.

KR103046375B1Active Publication Date: 2026-11-10LG CHEM LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020230136265
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-10-13
Filing Date
2023-10-12
Publication Date
2026-11-10
Estimated Expiration
2043-10-12

AI Technical Summary

Technical Problem

Existing antimicrobial agents, particularly quaternary ammonium compounds substituted with halogen anions, are limited by solubility in specific solvents, environmental toxicity concerns, and negative consumer perception, restricting their application in various products.

Method used

Development of compounds soluble in multiple solvents, including ether, toluene, and ethyl acetate, with anionic substitutions other than halogens, ensuring broad applicability and safety.

Benefits of technology

The compounds exhibit excellent antibacterial properties, stability in various solvents, and low toxicity, maintaining consistent antimicrobial activity despite concentration variations, suitable for diverse applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023112009518-PAT00025_ABST
    Figure 112023112009518-PAT00025_ABST
Patent Text Reader

Abstract

The present specification relates to a compound represented by Formula 1, which is soluble in at least two of ether, toluene, and ethyl acetate at room temperature, and a molded body comprising the same.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] This specification relates to compounds and molded articles containing the same.

[0002] This application claims the benefit of the filing date of Korean Patent Application No. 10-2022-0131730 filed with the Korean Intellectual Property Office on October 13, 2022, the entire contents of which are incorporated herein. Background Technology

[0003] Recently, high antibacterial properties are being required for various products, such as household goods and hygiene products.

[0004] The required degree of antimicrobial activity or the requirements for materials to impart antimicrobial properties vary depending on the materials of the product requiring antimicrobial properties or the conditions of final use. For example, the properties of the materials used to impart antimicrobial activity and the degree of antimicrobial activity differ depending on the amount of antimicrobial material applied to the product or the materials used in conjunction with it.

[0005] However, when introducing antimicrobial agents that inhibit bacterial growth into the resin in this manner, it was not easy to select and introduce an antimicrobial component that exhibits excellent bacterial growth inhibition properties while being harmless to the human body, satisfying economic feasibility, and not degrading the basic physical properties of the polymer resin.

[0006] As an example, most widely used quaternary ammonium antimicrobial agents are in the form substituted with halogen anions. However, in this case, there is a problem that their practicality is reduced because they are soluble only in specific solvents, and there is also a problem of negative consumer perception regarding antimicrobial agents containing halogens.

[0007] Therefore, there is a need to develop materials that are soluble in various solvents, exhibit high antibacterial properties, and are harmless to the human body as they do not release antibacterial substances.

[0008] [Prior Art] (Patent Document 1) Korean Patent Publication No. 10-2009-0131847 The problem to be solved

[0009] The present specification provides a compound and a molded body containing the same. means of solving the problem

[0010] One embodiment of the present specification is represented by the following chemical formula 1, and

[0011] Provides a compound that is soluble in at least two of ether, toluene, and ethyl acetate at room temperature.

[0012] [Chemical Formula 1]

[0013]

[0014] In the above chemical formula 1,

[0015] L1 is an alkylene group, and

[0016] R1 to R3 are identical or different from each other and are each independently alkyl groups, and at least one of R1 to R3 is an alkyl group having 5 to 30 carbon atoms,

[0017] R4 is hydrogen or an alkyl group, and

[0018] R - is a salicylate anion, a sulfate anion, a bisulfate anion, a benzoate anion, a sorbate anion, or a lactate anion.

[0019] Another embodiment of the present specification provides an antimicrobial composition comprising the aforementioned compound.

[0020] Another embodiment of the present specification provides a molded body comprising the aforementioned compound or manufactured therefrom. Effects of the invention

[0021] Compounds according to some embodiments of this specification are soluble in various solvents.

[0022] Compounds according to some embodiments of this specification have hydrophilicity and hydrophobicity and excellent antibacterial properties.

[0023] Compounds according to some embodiments of this specification can solve safety problems caused by the leakage of antimicrobial substances.

[0024] Compounds according to some embodiments of this specification can exhibit antibacterial properties within a short period of time.

[0025] Compounds according to some embodiments of this specification exhibit minimal variation in antimicrobial activity depending on the amount of antimicrobial material used; therefore, even when unintentional non-uniformity of concentration occurs during application to a product, they can exhibit antimicrobial activity within a predicted range. Consequently, the antimicrobial activity is controlled within a specific range, allowing for the safe provision of excellent antimicrobial activity.

[0026] Compounds according to some embodiments of this specification have low toxicity, so safety issues can be resolved. Brief explanation of the drawing

[0027] Figure 1 is R - Ga Br - This is a figure showing the NMR measurement results of phosphorus compound 12. Figure 2 is R - Ga Br - This is a figure showing the NMR measurement results of phosphorus compound 13. Figure 3 is R - The NMR measurement results of compound 13, which is a salicylate, were presented. Figure 4 is R - This is a figure showing the NMR measurement results of compound 13, which is a citrate. Figure 5 is R - This is a figure showing the NMR measurement results of compound 13, which is a sorbate. Figure 6 is R - This is a figure showing the NMR measurement results of compound 13, which is benzoate. Figure 7 is R - This is a figure showing the NMR measurement results of compound 12, which is a sulfate. Figure 8 is R - This is a picture showing the NMR measurement results of compound 12, which is a bisulfate. Figure 9 is a figure showing the TGA measurement results. Specific details for implementing the invention

[0028] The present specification will be described in detail below.

[0029] One embodiment of the present specification is represented by the following chemical formula 1, and

[0030] Provides a compound that is soluble in at least two of ether, toluene, and ethyl acetate at room temperature.

[0031] [Chemical Formula 1]

[0032]

[0033] In the above chemical formula 1,

[0034] L1 is an alkylene group, and

[0035] R1 to R3 are identical or different from each other and are each independently alkyl groups, and at least one of R1 to R3 is an alkyl group having 5 to 30 carbon atoms,

[0036] R4 is hydrogen or an alkyl group, and

[0037] R - is a salicylate anion, a sulfate anion, a bisulfate anion, a benzoate anion, a sorbate anion, or a lactate anion.

[0038] Conventionally, quaternary ammonium-based antimicrobial agents have been used in forms substituted with halogen anions. However, this presented a problem of reduced practicality as they were soluble only in specific solvents. Specifically, the conventionally used halogen anion (F - , Cl - , Br - or I - ) substituted quaternary ammonium compounds, in particular, represented by the above chemical formula 1 and R -Compounds that are halogen anions are soluble only in specific solvents such as ethanol, methylene chloride, and acetone, but not in ether, toluene, and ethyl acetate. This limits their application fields and has resulted in problems such as their inability to be used in lacquer-based paints, synthetic resin paints, and acrylic paints. Furthermore, there is a trend toward stricter regulatory measures regarding halogen-containing antimicrobial agents due to issues such as toxicity, potential for environmental pollution, and the need for careful handling due to high reactivity, and there is also the problem of negative consumer perception.

[0039] On the other hand, the compound according to the present specification does not contain a halogen group and contains other specific anions, thereby being soluble in various solvents, which has the advantage of improved practicality. Specifically, the compound represented by Chemical Formula 1 according to the present specification exhibits the effect of being soluble in various solvents that were not soluble when using halogen anions by changing the anion to a type other than a halogen anion. Therefore, by selectively using solvents as needed, it exhibits the effect of diversifying the fields of application of the compound.

[0040] In this specification, when a part is described as "comprising" a certain component, it means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.

[0041] In this specification, physical properties whose properties are affected by temperature are properties measured at room temperature, unless otherwise specifically defined.

[0042] In this specification, "room temperature" refers to a natural temperature that has not been heated or cooled, for example, any temperature within the range of about 10°C to 30°C, for example, about 15°C, about 18°C, about 20°C, about 23°C, or about 25°C. In addition, unless otherwise specifically defined in this specification, the unit of temperature is °C.

[0043] In this specification, where pressure affects the result among physical properties, unless specifically otherwise specified, said physical property is the property measured at atmospheric pressure.

[0044] In this specification, "atmospheric pressure" refers to natural pressure that is not pressurized or depressurized, and typically refers to about 1 atmosphere (about 700 to 800 mmHg).

[0045] In this specification, where humidity affects the result among physical properties, unless specifically otherwise specified, said physical property is a physical property measured at humidity that is not specifically controlled under the above-mentioned ambient temperature and pressure conditions.

[0046] In the present specification, the “alkyl group” may be a straight chain or a branched chain, and the number of carbon atoms is not particularly limited but is preferably 1 to 60. In one embodiment of the present specification, the number of carbon atoms of the alkyl group is 1 to 30. Specific examples of the alkyl group include, butyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, etc., but are not limited thereto.

[0047] In this specification, “alkylene group” means having two bonding positions to an alkyl group, i.e., a divalent group. Except for the fact that each of these is a divalent group, the description of the alkyl group described above may apply.

[0048] In the present specification, the “aryl group” may be monocyclic or polycyclic, and the number of carbon atoms is not particularly limited but is preferably 6 to 30. Specific examples of the aryl group include, but are not limited to, phenyl groups, biphenyl groups, terphenyl groups, naphthyl groups, anthracenyl groups, phenanthryl groups, triphenyl groups, etc.

[0049] In this specification, "dissolved" means that the solubility measured by Method 2 below is 3 g / L or more.

[0050] [Method 2]

[0051] 0.2g of the sample to be measured is taken, and solvent is added to make the total weight 6.6g. After stirring at 25℃ for 30 minutes, undissolved residual solute is removed. The amount of removed residual solute is measured to determine the amount of solute dissolved in the solvent, and the solubility is evaluated by converting the measured amount into a value per 1L of solvent. In the above, the removal of residual solute is performed by filtering the solution through a pore size of 0.45μm.

[0052] In one embodiment of the present specification, the compound is soluble in two of ether, toluene, and ethyl acetate at room temperature.

[0053] In one embodiment of the present specification, the compound is soluble in all three of ether, toluene, and ethyl acetate at room temperature.

[0054] In one embodiment of the present specification, the compound has a solubility in ether at room temperature of 3 g / L or more. Specifically, it is 5 g / L or more, or 10 g / L or more. The upper limit of the solubility is not particularly limited, and for example, the solubility is 100 g / L or less, 90 g / L or less, or 80 g / L or less.

[0055] In one embodiment of the present specification, the compound has a solubility in toluene of 3 g / L or more at room temperature. Specifically, it is 5 g / L or more, or 10 g / L or more. The upper limit of the solubility is not particularly limited, and for example, the solubility is 100 g / L or less, 90 g / L or less, or 80 g / L or less.

[0056] In one embodiment of the present specification, the solubility of the compound in ethyl acetate at room temperature is 3 g / L or more. Specifically, it is 5 g / L or more, or 10 g / L or more. The upper limit of the solubility is not particularly limited, and for example, the solubility is 100 g / L or less, 90 g / L or less, or 80 g / L or less.

[0057] In the present specification, the solubility being 3 g / L or higher means that 3 g or more of the compound is dissolved in 1 L of solvent.

[0058] In one embodiment of the present specification, the compound is soluble in ethanol, methylene chloride, and acetone (ACT) at room temperature.

[0059] In one embodiment of the present specification, L1 is an alkylene group having 1 to 10 carbon atoms.

[0060] In one embodiment of the present specification, L1 is an alkylene group having 1 to 5 carbon atoms.

[0061] In one embodiment of the present specification, L1 is a methylene group; an ethylene group; a propylene group; or a butylene group.

[0062] In one embodiment of the present specification, any one of R1 to R3 is an alkyl group having 5 to 30 carbon atoms, and the remainders are identical or different from each other and are each independently an alkyl group having 1 to 30 carbon atoms.

[0063] In one embodiment of the present specification, any one of R1 to R3 is an alkyl group having 5 to 30 carbon atoms, and the remainders are identical or different from each other and are each independently an alkyl group having 1 to 20 carbon atoms.

[0064] In one embodiment of the present specification, any one of R1 to R3 is an alkyl group having 5 to 30 carbon atoms, and the remainders are identical or different from each other and are each independently an alkyl group having 1 to 10 carbon atoms.

[0065] In one embodiment of the present specification, L1 is an alkylene group having 1 to 10 carbon atoms, any one of R1 to R3 is an alkyl group having 5 to 30 carbon atoms, and the remainder of R1 to R3 are the same or different from each other and are each independently an alkyl group having 1 to 30 carbon atoms.

[0066] In one embodiment of the present specification, L1 is an alkylene group having 1 to 5 carbon atoms, any one of R1 to R3 is an alkyl group having 5 to 30 carbon atoms, and the remainder of R1 to R3 are the same or different from each other and are each independently an alkyl group having 1 to 30 carbon atoms.

[0067] In one embodiment of the present specification, L1 is a methylene group, an ethylene group, or a butylene group, any one of R1 to R3 is an alkyl group having 5 to 30 carbon atoms, and the remainder of R1 to R3 are the same or different from each other and are each independently an alkyl group having 1 to 30 carbon atoms.

[0068] In one embodiment of the present specification, two or more of R1 to R3 are alkyl groups having 6 to 30 carbon atoms, or the difference in the number of carbon atoms between the alkyl group with the largest number of carbon atoms and the alkyl group with the smallest number of carbon atoms among R1 to R3 is 4 or more.

[0069] Specifically, three of R1 to R3 are alkyl groups having 6 to 30 carbon atoms; two of R1 to R3 are alkyl groups having 6 to 30 carbon atoms, and the remaining one is an alkyl group having 1 to 30 carbon atoms; or the difference in the number of carbon atoms between the alkyl group with the largest number of carbon atoms and the alkyl group with the smallest number of carbon atoms among R1 to R3 is 4 or more. In this case, excellent antibacterial activity is exhibited.

[0070] In one embodiment of the present specification, the difference in the number of carbon atoms between the alkyl group with the largest number of carbon atoms and the alkyl group with the smallest number of carbon atoms is 4 or more, which means that the asymmetry is large, and the difference in the number of carbon atoms may be 4 to 30, 5 to 30, or 5 to 10.

[0071] In one embodiment of the present specification, the compound is any one of the following structures.

[0072]

[0073] In the above structure, R - It is as previously stated.

[0074] In one embodiment of the present specification, the salicylate-based anion is It is represented as such, where R10 is hydrogen; an alkyl group; or an aryl group, and r10 is an integer from 1 to 4.

[0075] In one embodiment of the present specification, R of Formula 1 - When α is a salicylate anion, the compound exhibits solid properties.

[0076] In one embodiment of the present specification, R10 is hydrogen.

[0077] In one embodiment of the present specification, the benzoate-based anion is It is represented as such, where R11 is hydrogen; an alkyl group; or an aryl group, and r11 is an integer from 1 to 5.

[0078] In one embodiment of the present specification, R of Formula 1 - When α is a benzoate anion, the compound exhibits liquid characteristics.

[0079] In one embodiment of the present specification, R11 is hydrogen.

[0080] In one embodiment of the present specification, the sorbate-based anion is It is displayed as.

[0081] In one embodiment of the present specification, R of Formula 1 - When ga is a sorbate-based anion, the compound exhibits solid properties.

[0082] In one embodiment of the present specification, the lactate-based anion is It is displayed as.

[0083] In one embodiment of the present specification, R of Formula 1 - When ga is a lactate anion, the compound exhibits solid properties.

[0084] In one embodiment of the present specification, the sulfate-based anion is It is represented as , and R12 is an alkyl group.

[0085] In one embodiment of the present specification, R of Formula 1 - When α is a sulfate anion, the compound exhibits solid properties.

[0086] In one embodiment of the present specification, the bisulfate-based anion is It is represented as , and R12 is hydrogen.

[0087] In one embodiment of the present specification, R of Formula 1 - When α is a bisulfate anion, the compound exhibits solid properties.

[0088] In this specification, unless specifically limited, the number of carbon atoms of the alkyl group may refer to an alkyl group having 1 to 30 carbon atoms, and unless specifically limited, the number of carbon atoms of the aryl group may refer to an aryl group having 6 to 30 carbon atoms, and the substituents thereof are known in the art and are not specifically limited as long as they do not deviate from the intent of the present invention.

[0089] As described above, the properties of a compound vary depending on the type of anionic group. That is, in one embodiment of this specification, the properties of the compound can be controlled through anionic substitution. Therefore, the compound according to one embodiment of this specification exhibits the effect of diversifying the fields of application of the compound by selectively substituting anions as needed.

[0090] In one embodiment of the present specification, the R - is one of the following structures.

[0091]

[0092] In the above structure,

[0093] R10 to R12 are identical or different from one another, and each is independently hydrogen; an alkyl group; or an aryl group, and

[0094] r10 is an integer from 1 to 4, and if r10 is 2 or greater, 2 or more R10s are identical or different from each other, and

[0095] r11 is an integer from 1 to 5, and if r11 is 2 or more, 2 or more R11s are identical or different from each other.

[0096] In one embodiment of the present specification, the compound remains dissolved in the solvent without precipitating even after a certain period of time. That is, the compound exhibits solubility stability.

[0097] In one embodiment of the present specification, the compound has antibacterial properties.

[0098] In this specification, having antibacterial properties means having antibacterial activity measured according to Method 1 below, in other words, a bacteriostatic reduction rate of 90% or more.

[0099] In one embodiment of the present specification, the compound has a bacteriostatic reduction rate of 90% or more, measured by Method 1 below, against at least one strain selected from the group consisting of Gram-positive bacteria, Gram-negative bacteria, and fungi.

[0100] [Method 1]

[0101] Transfer 20 mL of broth-type medium (Nutrient broth, BD DIFCO., 8 g / L) inoculated with 3000 CFU / mL of bacteria into a 50 mL conical tube, then add 0.005 g, 0.01 g, 0.015 g, or 0.020 g of the compound and vortex. Incubate the thoroughly mixed solution for 16 hours in a shaking water bath maintained at 35°C. After incubation is complete, dilute the solution to 1 / 5 using 1X PBS buffer solution, and measure the absorbance at a wavelength of 600 nm using a UV / Vis spectrophotometer. Compare the measured absorbance with the solution incubated without the bacteriostatic substance to calculate the bacteriostatic reduction rate using the following formula.

[0102] [Mathematical Formula 1]

[0103]

[0104] In the present specification, the antibacterial substance of the above mathematical formula 1 is a compound of the above chemical formula 1.

[0105] In this specification, CFU (Colony Forming Unit) means a colony-forming unit, and CFU / mL means the number of CFUs per 1 mL.

[0106] When the bacteriostatic reduction rate was evaluated for the compound of the present specification using Method 1, only cases where the bacteriostatic reduction rate (antibacterial activity) was 92% or higher were observed. Consequently, it was confirmed that the compound according to the present specification has excellent antibacterial activity.

[0107] In this specification, Gram-positive bacteria are a general term for bacteria that stain purple when stained by Gram staining. The cell walls of Gram-positive bacteria are composed of multiple layers of peptidoglycan, so they do not lose color and show purple even when treated with ethanol after being stained with a basic dye such as crystal violet.

[0108] In one embodiment of the present specification, the Gram-positive bacteria are selected from Enterococcus faecalis, Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecium, and Lactobacillus lactis. Specifically, any one selected from the examples described above, but is not limited thereto.

[0109] In this specification, Gram-negative bacteria are a general term for bacteria that stain red when stained by Gram staining, and have a cell wall having a relatively small amount of peptidoglycan compared to Gram-positive bacteria, and instead have an outer membrane composed of lipopolysaccharides, lipoproteins and / or other complex macromolecules.

[0110] In one embodiment of the present specification, the Gram-negative bacteria are selected from Proteus mirabilis, Escherichia coli, Salmonella typhi, Pseudomonas aeruginosa, and Vibrio cholerae. Specifically, any one selected from the examples described above is selected, but is not limited thereto.

[0111] In one embodiment of the present specification, the fungus may be Candida albicans, but is not limited thereto.

[0112] In one embodiment of the present specification, the compound has an antibacterial activity of 90% or more against Gram-positive bacteria as measured by Method 1.

[0113] In one embodiment of the present specification, the compound has an antibacterial activity of 90% or more against Gram-negative bacteria as measured by Method 1.

[0114] Since the above-mentioned Gram-positive bacteria, Gram-negative bacteria, and fungal strains can cause various diseases upon contact and also cause secondary infections, it is desirable to use a single compound to exhibit antibacterial activity against all of the above-mentioned Gram-positive bacteria, Gram-negative bacteria, and fungi.

[0115] In one embodiment of the present specification, the compound has an acute oral toxicity concentration LD50 greater than 300 mg / Kg, preferably 320 mg / Kg or more. It is advantageous for the compound according to the aforementioned embodiments to have lower toxicity as the acute oral toxicity concentration LD50 is higher. However, the value of the LD50 may be determined from the perspective that the aforementioned antimicrobial activity must also be satisfied. For example, the acute oral toxicity concentration LD50 of the compound may be 50,000 mg / Kg or less, and may be, for example, 10,000 mg / Kg or less, 5,000 mg / Kg or less, or 2,000 mg / Kg or less. In one example, the acute oral toxicity concentration LD50 of the compound according to the aforementioned embodiments may be 1,000 mg / Kg or less.

[0116] One embodiment of the present specification provides an antimicrobial composition comprising the aforementioned compound.

[0117] In one embodiment of the present specification, the above-described antimicrobial composition further comprises a solvent, said solvent being at least one of ether, toluene, ethyl acetate, acetone, water, acetonitrile, ethanol, dichloromethane, chloroform, and hexane.

[0118] In one embodiment of the present specification, the solvent included in the antimicrobial composition is one to 10 types, one to 7 types, one to 5 types, one to 3 types, or one type among the aforementioned solvents.

[0119] In one embodiment of the present specification, the solvent included in the antimicrobial composition is one to three types selected from ether, toluene, and ethyl acetate.

[0120] In one embodiment of the present specification, the solvent included in the antimicrobial composition is one of ether, toluene, and ethyl acetate.

[0121] One embodiment of the present specification provides a molded article comprising the aforementioned antimicrobial resin or manufactured therefrom. Specifically, the molded article may be an automotive part, a blow-molded article, an inflation-molded article, a cast-molded article, an extrusion-laminate-molded article, an extrusion-molded article, a foam-molded article, an injection-molded article, a sheet, a film, a fiber, a monofilament, or a nonwoven fabric, but is not limited to the above examples. The automotive part may be an interior or exterior material for an automobile, etc.

[0122] Hereinafter, to specifically explain this specification, examples will be described in detail. However, the embodiments according to this specification may be modified in various different forms, and the scope of this specification is not to be interpreted as being limited to the embodiments described below. The embodiments of this specification are provided to more completely explain this specification to those with average knowledge in the art.

[0123] <Preparation Example 1>

[0124] Preparation Example 1-1. Synthesis of Compound 1

[0125] Step 1.

[0126] (1) 0.1 mol 2-(dibutylamino)ethanol (DBAE, 2-(dibutylamino)ethanol), 0.1 mol trimethylamine and 0.001 mol hydroquinone were added to 100 mL of THF (solvent).

[0127] (2) While stirring the above materials, 0.1 mol acryloyl chloride was added dropwise to the reaction solution (at room temperature).

[0128] (3) Stirred for 2 hours.

[0129] (4) After removing the triethylamine salt by filtration, the solvent was removed using a rotary evaporator.

[0130] (5) Vacuum dried at 83 ℃ to 87 ℃.

[0131] Step 2.

[0132] (1) The product of Step 1 and 1-bromooctane were dissolved in acrylonitrile (solvent) at a ratio of 1:1 molar to 50 wt%.

[0133] (2) Next, p-methoxyphenol, a polymerization inhibitor, was added (ratio with reactants 1:0.001 (eq)).

[0134] (3) Reacted at 50 ℃ for 20 hours.

[0135] (4) After precipitating in methyl t-butyl ether (MTBE, methyl t-butyl ether) (MTBE:reaction solution = 15:1 (volume ratio)), it was filtered.

[0136] (5) Vacuum dried at 45 ℃.

[0137] Step 3.

[0138] (1) The product of step 2 above was dissolved in water.

[0139] (2) Dissolve the salt in water.

[0140] (3) The two solutions prepared in (1) and (2) above were mixed and stirred for one day.

[0141] (4) After the reaction, the organic layer was extracted using ethyl acetate to produce Compound 1.

[0142] Depending on the type of compound to be prepared, the salt used in step 3 above was sodium salicylate, sodium citrate, sodium benzoate, or sodium benzoate.

[0143] Preparation Example 1-2. Synthesis of Compounds 2 and 3

[0144] Compounds 2 and 3 were prepared in the same manner as in Preparation Example 1-1, except that in step 2 (1) of Preparation Example 1-1, 1-bromodecane (1-boromodecane, preparation of compound 2) or 1-bromododecane (1-boromododecane, preparation of compound 3) was used instead of 1-bromooctane.

[0145] Preparation Example 1-3. Synthesis of Compound 4

[0146] Compound 4 was prepared in the same manner as in Preparation Example 1-1, except that in step 1 (1) of Preparation Example 1-1, 2-(dioctylamino)ethanol (DOAE, 2-(Dioctylamino)ethanol) was used instead of 2-(dibutylamino)ethanol.

[0147] Preparation Example 1-4. Synthesis of Compound 5

[0148] Step 1.

[0149] (1) 0.1 mol 2-(dihexylamino)ethanol (DHAE, 2-(Dihexylamino)ethanol), 0.1 mol trimethylamine and 0.001 mol hydroquinone were added to 100 mL of THF (solvent).

[0150] (2) While stirring the above materials, 0.1 mol acryloyl chloride was added dropwise to the reaction solution (at room temperature).

[0151] (3) Stirred for 2 hours.

[0152] (4) After removing the triethylamine salt by filtration, the solvent was removed using a rotary evaporator.

[0153] (5) Vacuum dried at 83 ℃ to 87 ℃.

[0154] Step 2.

[0155] (1) The product of Step 1 and 1-bromodecane were dissolved in acrylonitrile (solvent) at a ratio of 1:1 molar to 50 wt%.

[0156] (2) Next, p-methoxyphenol, a polymerization inhibitor, was added (ratio with reactants 1:0.001 (eq)).

[0157] (3) Reacted at 50 ℃ for 20 hours.

[0158] (4) After precipitating in methyl t-butyl ether (MTBE, methyl t-butyl ether) (MTBE:reaction solution = 15:1 (volume ratio)), it was filtered.

[0159] (5) Vacuum dried at 45 ℃.

[0160] Step 3.

[0161] (1) The product of step 2 above was dissolved in water.

[0162] (2) Dissolve the salt in water.

[0163] (3) The two solutions prepared in (1) and (2) above were mixed and stirred for one day.

[0164] (4) After the reaction, the organic layer was extracted using ethyl acetate to produce Compound 1.

[0165] Depending on the type of compound to be prepared, the salt used in step 3 above was sodium salicylate, sodium citrate, or sodium benzoate.

[0166] Preparation Examples 1-5. Synthesis of Compound 6

[0167] Compound 6 was prepared in the same manner as in Preparation Example 1-4, except that in step 1 (1) of Preparation Example 1-4, 2-(butylhexylamino)ethanol (BHAE, 2-(butylhexylamino)ethanol)) was used instead of 2-(dihexylamino)ethanol.

[0168] Preparation Examples 1-6. Synthesis of Compound 7

[0169] Compound 7 was prepared in the same manner as in Preparation Example 1-4, except that in step 1 (1) of Preparation Example 1-4, 2-(butyloctylamino)ethanol (BOAE, 2-(butyloctylamino)ethanol) was used instead of 2-(dihexylamino)ethanol.

[0170] Preparation Examples 1-7. Synthesis of Compound 8

[0171] Compound 8 was prepared in the same manner as in Preparation Example 1-4, except that in step 1 (1) of Preparation Example 1-4, 2-(butyldecylamino)ethanol (BOAE, 2-(butyldecylamino)ethanol) was used instead of 2-(dihexylamino)ethanol.

[0172] Preparation Examples 1-8. Synthesis of Compound 9

[0173] Compound 9 was prepared in the same manner as in Preparation Example 1-1, except that in step 1 (1) of Preparation Example 1-1, 2-(dibutylamino)butanol (DBAB, 2-(Dibutylamino)butanol) was used instead of 2-(dibutylamino)ethanol.

[0174] Preparation Example 1-9. Synthesis of Compound 10

[0175] Compound 10 was prepared in the same manner as in Preparation Example 1-1, except that in step 1 (1) of Preparation Example 1-1, 2-(dioctylamino)butanol (DOAB, 2-(Dioctylamino)butanol) was used instead of 2-(dibutylamino)ethanol.

[0176] Preparation Examples 1-10. Synthesis of Compound 11

[0177] Step 1.

[0178] (1) 5.3 g of 1-bromooctane, 3.7 g of 2-(dimethylamino)ethyl methacrylate, 89.4 mg of 4-methoxyphenol, and 12 mL of acetonitrile were added to a two-neck RBF (Round Bottom Flask).

[0179] (2) Reacted at 60℃ for 6 hours.

[0180] (3) After precipitating in methyl t-butyl ether (MTBE, methyl t-butyl ether) (MTBE:reaction solution = 15:1 (volume ratio)), it was filtered.

[0181] (4) Vacuum dried at 45 ℃.

[0182] Step 2.

[0183] (1) The product of step 1 above was dissolved in water.

[0184] (2) The salt to be replaced was dissolved in water.

[0185] (3) The two solutions prepared in (1) and (2) above were mixed and stirred for one day.

[0186] (4) After the reaction, the organic layer was extracted using ethyl acetate to produce Compound 1.

[0187] Depending on the type of compound to be prepared, the above salt used was sodium salicylate, sodium citrate, sodium benzoate, sodium sorbate, or sodium bisulfate.

[0188] However, when sodium dodecyl sulfate is used as the salt to be substituted, an excess amount of sodium chloride is added after the reaction is finished in step 3 (4) to extract (salting out) the compound.

[0189] Preparation Examples 1-11. Synthesis of Compounds 12 and 13

[0190] Compounds 12 and 13 were prepared in the same manner as in Preparation Examples 1-10, except that 1-bromodecane (preparation of compound 12) or 1-bromododecane (preparation of compound 13) was used instead of 1-bromooctane in Preparation Examples 1-10.

[0191] R - Ga Br - Phosphorus compounds 12 and 13 were obtained by terminating the reaction in Step 1 of Preparation Examples 1-10 and 1-11 above.

[0192] In the above Preparation Examples 1-1 to 1-11, a forward precipitation method in which the reactants are introduced into a nonsolvent was used, but a reverse precipitation method in which the nonsolvent is introduced into the reactants may also be used. In addition, the ratio of MTBE to the reaction solution may be other than 15:1, for example, 12:1 or 26:1 may be used.

[0193] The structures of compounds 1 to 13 prepared in the above Preparation Examples 1-1 to 1-11 are as follows.

[0194]

[0195] * R - : Salicylate ( ), citrate( ), benzoate( ), Soveit( ), sulfate( ), or bisulfate( )lim

[0196] It was confirmed through NMR measurement that the above compounds 1 to 13, substituted with specific anions, were synthesized.

[0197] In Fig. 1, R - Ga Br - The NMR measurement results of phosphorus compound 12 are shown.

[0198] In Fig. 2, R - Ga Br - The NMR measurement results of phosphorus compound 13 are shown.

[0199] In Fig. 3, R - The NMR measurement results of compound 13, which is a salicylate, were presented.

[0200] In Fig. 4, R - The NMR measurement results of compound 13, which is a citrate, were presented.

[0201] In Fig. 5, R - The NMR measurement results of compound 13, which is a sorbate, were presented.

[0202] In Fig. 6, R - The NMR measurement results of compound 13, which is benzoate, were presented.

[0203] In Fig. 7, R - The NMR measurement results of compound 12, which is a sulfate, were presented.

[0204] In Fig. 8, R - The NMR measurement results of compound 12, which is a bisulfate, were presented.

[0205] <Experimental Example 1> Measurement of Solubility

[0206] 0.2g of the sample was taken, and solvent was added to make the total weight 6.6g. After stirring at 25℃ for 30 minutes, undissolved residual solute was removed. The amount of removed residual solute was measured to determine the amount of solute dissolved in the solvent, and the solubility was evaluated by converting the measured amount into a value per 1L of solvent. In the above, the removal of residual solute was performed by filtering the solution through a pore size of 0.45μm.

[0207] The measurement target is Compound 13 prepared in Preparation Examples 1-11 above, wherein R - Each type was designated as shown in Table 1 below.

[0208] The results of the solubility measurement are listed in Table 1 below.

[0209] No. R - Solubility ethanol methylene chloride acetone ether toluene ethyl acetate Comparative Example 1-1 Br - O O O X X X Comparative Example 1-2 Citrate O O O X X O Example 1-1 salicylate O O O X O O Example 1-2 Benzoate O X O O O O Examples 1-3 Soveit X X O O O O Examples 1-4 Sulfate O O O X O O Examples 1-5 Bisulfate O O O O O O

[0210] - O: Solubility 3g / L or higher

[0211] - X: Solubility less than 3 g / L

[0212] From Table 1 above, a halogen group (specifically Br) as the anion of the compound - It can be confirmed that solubility in various solvents can be improved by including specific anions other than ) or citrate.

[0213] <Experimental Example 2> Measurement of Antibacterial Activity

[0214] 20 mL of broth-type medium (Nutrient broth, BD DIFCO., 8 g / L) inoculated with 3000 CFU / mL of E. coli was transferred to a 50 mL conical tube, and 0.005 g, 0.01 g, 0.015 g, or 0.020 g of the compound was added and vortexed. The thoroughly mixed solution was incubated for 16 hours in a shaking incubator maintained at 35°C. After incubation was complete, the solution was diluted 1 / 5 with 1X PBS buffer solution, and the absorbance at a wavelength of 600 nm was measured using a UV / Vis spectrophotometer. The bacteriostatic reduction rate was calculated using the following formula by comparing the measured absorbance with the solution incubated without the bacteriostatic substance.

[0215] The measurement target is Compound 13 prepared in Preparation Examples 1-11 above, wherein R - Depending on the type, they were referred to as shown in Table 2 below.

[0216] [Mathematical Formula 1]

[0217]

[0218] The derived bacteriostatic reduction rate (antibacterial activity) is listed in Table 2 below.

[0219] No. R - antibacterial power 0.5 phr 1 phr 1.5 phr 2 phr Comparative Example 2-1 Br - 91.9 91.5 91.9 93.1 Comparative Example 1-2 Citrate 92.9 92.8 92.9 93.2 Example 2-1 salicylate 95.7 95.7 95.8 95.7 Example 2-2 Benzoate 96.1 96.2 96.1 96.3 Examples 2-3 Soveit 95.1 95.3 95.3 95.7 Examples 2-5 Sulfate 95.2 95.8 95.7 96.1 Examples 2-6 Bisulfate 95.7 96.1 96.2 96.2

[0220] In Table 2 above, 0.5 phr, 1 phr, 1.5 phr, and 2 phr are as follows, respectively.

[0221] - 0.5 phr: Add 0.005 g of the compound to 20 mL of a 3000 CFU / mL bacterial solution

[0222] - 1 phr: Add 0.01 g of the compound to 20 mL of a 3000 CFU / mL bacterial solution

[0223] - 1.5 phr: Add 0.015 g of the compound to 20 mL of a 3000 CFU / mL bacterial solution

[0224] - 2 phr: Add 0.02 g of the compound to 20 mL of a 3000 CFU / mL bacterial solution

[0225] From Table 2 above, the compound according to one embodiment of the present specification, by using a specific anion, Br - It can be confirmed that it exhibits antibacterial activity equivalent to or greater than that of compounds containing citrate when compared with compounds containing citrate.

[0226] <Experimental Example 3> Toxicity and Stability Evaluation

[0227] The acute oral toxicity concentration LD50 was measured according to the 3T3 Neutral Red Uptake (NRU) assay (OECD Guidance Document NO 129). Specifically, the LD50 was calculated as follows.

[0228]

[0229] The calculated results are shown in Table 3 below.

[0230] The measurement target is Compound 13 prepared in Preparation Examples 1-11 above, wherein R - Depending on the type, they were referred to as shown in Table 3 below.

[0231] No. R - LD50 (mg / kg) Comparative Example 3-1 Br - 518 Comparative Example 3-2 Citrate 327 Example 3-1 salicylate 590 Example 3-2 Benzoate 582 Example 3-3 Soveit 322

[0232] From Table 3 above, it can be seen that the compound according to one embodiment of the present specification has an LD50 that falls into acute toxicity standard category 4 (300 mg / kg to 2,000 mg / kg), just as in the case where a halogen group is applied as an anion and when a citrate is applied.

[0233] Accordingly, from Tables 1 to 3 above, the compound according to one embodiment of this specification, by using a specific anion, has an acute toxicity standard of Br - It can be confirmed that while belonging to equivalent category 4, such as citrate, the antibacterial activity is improved and the types of solvents that dissolve are diverse.

[0234] <Experimental Example 4> Heat Resistance Evaluation

[0235] In this experiment, heat resistance was evaluated as the extrapolated intersection point (first pyrolysis temperature) between the starting mass reference line and the tangent line of the maximum slope point in the first mass loss section of the mass loss curve measured by a thermogravimetric analyzer (TGA) in an N2 atmospheric environment.

[0236] In the present invention, it was determined that the heat resistance increased when the primary thermal decomposition temperature of the compound had a higher value compared to the primary thermal decomposition temperature of the material before anion substitution. The measurement results are as described in Fig. 9 below.

[0237] The measurement target is Compound 12 prepared in Preparation Examples 1-11 above, wherein R - Depending on the type, Comparative Example 4-1 and Example 4-1 are described in FIG. 9, respectively.

[0238] Referring to Fig. 9, the anion is Br - The Td (pyrolysis temperature) of Comparative Example 4-1 is approximately 230°C, which confirms that the heat resistance is improved compared to Example 4-1, in which the anion is substituted with bisulfate.

Claims

Claim 1 An antimicrobial composition comprising a compound represented by the following chemical formula 1 in a non-polymerized form, wherein the compound is soluble in at least two of ether, toluene, and ethyl acetate at room temperature: [Chemical Formula 1] In the above Chemical Formula 1, L1 is a methylene group; an ethylene group; a propylene group; or a butylene group; any one of R1 to R3 is an alkyl group having 5 to 30 carbon atoms; the remainders are identical or different from each other and are each independently an alkyl group having 1 to 20 carbon atoms; R4 is hydrogen or a methyl group; and R - is a salicylate anion, a sulfate anion, a bisulfate anion, a benzoate anion, or a sorbate anion. Claim 2 In claim 1, the R - An antimicrobial composition having any one of the following structures: In the above structure, R10 to R12 are identical or different from each other and each independently hydrogen; an alkyl group; or an aryl group, r10 is an integer from 1 to 4, and if r10 is 2 or more, 2 or more R10s are identical or different from each other, r11 is an integer from 1 to 5, and if r11 is 2 or more, 2 or more R11s are identical or different from each other. Claim 3 delete Claim 4 An antimicrobial composition according to claim 1, wherein the compound is any one of the following structures: In the above structure, R - is identical to that defined in Claim 1. Claim 5 The antimicrobial composition of claim 1, wherein the bacteriostatic reduction rate measured by Method 1 below is 90% or higher for at least one strain selected from the group consisting of Gram-positive bacteria, Gram-negative bacteria, and fungi: [Method 1] 20 mL of broth-type medium (Nutrient broth, BD DIFCO., 8 g / L) inoculated with 3000 CFU / mL of bacteria is transferred to a 50 mL conical tube, and then 0.005 g, 0.01 g, 0.015 g, or 0.020 g of a compound is added and vortexed. The sufficiently mixed solution is incubated for 16 hours in a shaking incubator maintained at 35°C. After incubation is complete, the solution is diluted to 1 / 5 using 1X PBS buffer solution, and the absorbance at a wavelength of 600 nm is measured using a UV / Vis spectrophotometer. The bacteriostatic reduction rate is calculated by comparing the measured absorbance with a solution cultured without a bacteriostatic substance using the following formula. [Equation 1] Claim 6 The antimicrobial composition of claim 5, wherein the Gram-positive bacteria are selected from Enterococcus faecalis, Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecium, and Lactobacillus lactis. Claim 7 The antimicrobial composition of claim 5, wherein the Gram-negative bacteria are selected from Proteus mirabilis, Escherichia coli, Salmonella typhi, Pseudomonas aeruginosa, and Vibrio cholerae. Claim 8 delete Claim 9 An antimicrobial composition according to claim 1, further comprising a solvent, wherein the solvent is at least one of ether, toluene, ethyl acetate, acetone, water, acetonitrile, ethanol, dichloromethane, chloroform, and hexane. Claim 10 A molded body comprising an antimicrobial composition according to any one of claims 1, 2, 4 to 7 and 9, or manufactured therefrom.

Citation Information

Patent Citations

  • Polymer having biocidal activity, and method for producing and use of the same

    JP2003306404A

  • Surface treatment method by photopolymerization to obtain biocidal properties

    JP2006507111A